Literature DB >> 28031410

Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma.

Fen Zhu1,2, Byounghoon Hwang2,3, Shigeki Miyamoto2,3, Lixin Rui4,2.   

Abstract

JAKs are non-receptor tyrosine kinases that are generally found in association with cytokine receptors. In the canonical pathway, roles of JAKs have well been established in activating STATs in response to cytokine stimulation to modulate gene transcription. In contrast, a noncanonical role of JAK2 has recently been discovered, in which JAK2 in the nucleus imparts the epigenetic regulation of gene transcription through phosphorylation of tyrosine 41 on the histone protein H3. Recent work further demonstrated that this noncanonical mechanism is conserved with JAK1, which is activated by the autocrine cytokines IL6 and IL10 in activated B-cell-like diffuse large B-cell lymphoma (ABC DLBCL), a cancer type that is particularly difficult to treat and has poor prognosis. However, how JAK1 gains access to the nucleus to enable epigenetic regulation remains undefined. Here, we investigated this question and revealed that JAK1 has a classical nuclear localization signal toward the N-terminal region, which can be recognized by multiple importin α isoforms. Moreover, the nuclear import of JAK1 is independent of its kinase activity but is required for the optimal expansion of ABC DLBCL cells in vitroImplications: This study demonstrates that the nuclear import of JAK1 is essential for the optimal fitness of ABC DLBCL cells, and targeting JAK1 nuclear localization is a potential therapeutic strategy for ABC DLBCL. Mol Cancer Res; 15(3); 348-57. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28031410      PMCID: PMC5473959          DOI: 10.1158/1541-7786.MCR-16-0344

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  54 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

Review 2.  Importins and beyond: non-conventional nuclear transport mechanisms.

Authors:  Kylie M Wagstaff; David A Jans
Journal:  Traffic       Date:  2009-04-29       Impact factor: 6.215

3.  v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells.

Authors:  T D Gilmore; H M Temin
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase.

Authors:  P A Ram; D J Waxman
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

6.  Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C.

Authors:  G M Pieper
Journal:  J Cardiovasc Pharmacol       Date:  1997-10       Impact factor: 3.105

Review 7.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Authors:  Elisabeth Losdyck; Tekla Hornakova; Lorraine Springuel; Sandrine Degryse; Olga Gielen; Jan Cools; Stefan N Constantinescu; Elisabetta Flex; Marco Tartaglia; Jean-Christophe Renauld; Laurent Knoops
Journal:  J Biol Chem       Date:  2015-10-07       Impact factor: 5.157

9.  A mix of S and ΔS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture.

Authors:  M Zheng; K B Turton; F Zhu; Y Li; K M Grindle; D S Annis; L Lu; A C Drennan; D J Tweardy; U Bharadwaj; D F Mosher; L Rui
Journal:  Oncogenesis       Date:  2016-01-04       Impact factor: 7.485

10.  Three distinct patterns of histone H3Y41 phosphorylation mark active genes.

Authors:  Mark A Dawson; Samuel D Foster; Andrew J Bannister; Samuel C Robson; Rebecca Hannah; Xiaonan Wang; Blerta Xhemalce; Andrew D Wood; Anthony R Green; Berthold Göttgens; Tony Kouzarides
Journal:  Cell Rep       Date:  2012-09-20       Impact factor: 9.423

View more
  9 in total

Review 1.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

2.  Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.

Authors:  Li Lu; Fen Zhu; Meili Zhang; Yangguang Li; Amanda C Drennan; Shuichi Kimpara; Ian Rumball; Christopher Selzer; Hunter Cameron; Ashley Kellicut; Amanda Kelm; Fangyu Wang; Thomas A Waldmann; Lixin Rui
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-02       Impact factor: 11.205

3.  The Seminiferous Epithelial Cycle of Spermatogenesis: Role of Non-receptor Tyrosine Kinases.

Authors:  Xiang Xiao; Dongwang Zheng; Fei Liang; Shibo Ying; Peibei Sun; Jianmin Yu; Ya Ni
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  EGR1 Addiction in Diffuse Large B-cell Lymphoma.

Authors:  Shuichi Kimpara; Li Lu; Nguyet M Hoang; Fen Zhu; Paul D Bates; Anusara Daenthanasanmak; Shanxiang Zhang; David T Yang; Amanda Kelm; Yunxia Liu; Yangguang Li; Alexander Rosiejka; Apoorv Kondapelli; Samantha Bebel; Madelyn Chen; Thomas A Waldmann; Christian M Capitini; Lixin Rui
Journal:  Mol Cancer Res       Date:  2021-05-12       Impact factor: 5.852

5.  Janus Kinase 1 Is Required for Transcriptional Reprograming of Murine Astrocytes in Response to Endoplasmic Reticulum Stress.

Authors:  Savannah G Sims; Gordon P Meares
Journal:  Front Cell Neurosci       Date:  2019-10-11       Impact factor: 5.505

Review 6.  Targeting nuclear import and export in hematological malignancies.

Authors:  Boaz Nachmias; Aaron D Schimmer
Journal:  Leukemia       Date:  2020-07-05       Impact factor: 11.528

7.  JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).

Authors:  Chella Krishna Vadivel; Maria Gluud; Sara Torres-Rusillo; Lasse Boding; Andreas Willerslev-Olsen; Terkild B Buus; Tea Kirkegaard Nielsen; Jenny L Persson; Charlotte M Bonefeld; Carsten Geisler; Thorbjorn Krejsgaard; Anja T Fuglsang; Niels Odum; Anders Woetmann
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

8.  Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL).

Authors:  Pengcheng Feng; Hongxia Li; Jinhong Pei; Yan Huang; Guixia Li
Journal:  Front Genet       Date:  2021-02-10       Impact factor: 4.599

Review 9.  STAT3 Activation and Oncogenesis in Lymphoma.

Authors:  Fen Zhu; Kevin Boyang Wang; Lixin Rui
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.